Business Context and Reporting Period
This Form 6-K filing by Gold Fields Limited, a South African incorporated entity, covers the month of June 2011. The report discloses a material transaction regarding executive compensation in compliance with the Listings Requirements of the Johannesburg Stock Exchange (JSE).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the grant of equity-based compensation instruments.
Material Changes and Transactions
On March 1, 2011, Gold Fields Limited granted Share Appreciation Rights (SARS) and Performance Vesting Restricted Shares (PVRS) to directors. These offers were accepted between June 2 and June 6, 2011. Key terms include:
- SARS: Allocated at a strike price of R119.15 (volume weighted average price over 20 trading days preceding the grant date). They vest after three years with a three-year exercise window thereafter. Settlement may be in shares or cash at the company's discretion.
- PVRS: Conditionally awarded with a strike price of Nil. The final number of shares settled ranges from 0% to 300% of the conditional award based on performance criteria met over three years. Settlement may be in shares or cash.
Specific grants to named directors include:
| Director Name | Position | SARS Granted | PVRS Granted |
|---|---|---|---|
| J Pauley | Director of major subsidiaries | 3,825 | 2,175 |
| PA Schmidt | Executive Director | 12,900 | 16,300 |
| NJ Holland | Executive Director | 19,125 | 26,250 |
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding operational performance. The primary contingency noted is the performance-based nature of the PVRS, where the final settlement amount depends on meeting specific criteria over a three-year period. The company retains discretion to settle awards in cash or shares.
Investor Verification Checklist
- Verify the impact of the R119.15 SARS strike price relative to the current market price of Gold Fields shares.
- Review the specific performance criteria attached to the PVRS to assess the likelihood of the 0% to 300% settlement range.
- Confirm the total dilution potential if all SARS and PVRS are settled in shares rather than cash.
- Check subsequent filings for the actual vesting and exercise activity of these instruments.